Our understanding of prostate cancer (PCa) has shifted from solely caused by a few genetic aberrations to a combination of complex biochemical dysregulations with the prostate metabolome at its core. The role of metabolomics in analyzing the pathophysiology of PCa is indispensable. However, to fully elucidate real-time complex dysregulation in prostate cells, an integrated approach based on metabolomics and other omics is warranted. Individually, genomics, transcriptomics, and proteomics are robust, but they are not enough to achieve a holistic view of PCa tumorigenesis. This review is the first of its kind to focus solely on the integration of metabolomics with multi-omic platforms in PCa research, including a detailed emphasis on the metabolomic profile of PCa. The authors intend to provide researchers in the field with a comprehensive knowledge base in PCa metabolomics and offer perspectives on overcoming limitations of the tool to guide future point-of-care applications.
|State||Published - Jun 2022|
Bibliographical noteFunding Information:
This work was funded by NIH NIGMS P20GM121327 and NIH NCI R03 R03CA256230 (K. Fong) This research is also supported by the start-up fund from the University of Kentucky Markey Cancer Center (K. Fong).
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
- prostate cancer
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Molecular Biology